Delivery Order HHSN261201200020I-HHSN26100007
Award Date 9/12/14
Potential Completion Date 9/11/17
Potential Value $607K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,029,991.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Oklahoma Health Sciences Center. The order is for the "Further Evaluation of AMHR2-ED Antigens for Epithelial Ovarian Carcinoma" project, which aims to conduct research related to epithelial ovarian cancer. The award is part of the larger PREVENT Preclinical Drug Development Program (PREVENT), an Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle...
- This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
- The National Cancer Institute awarded a $1.23M firm fixed-price delivery order to the University of Oklahoma Health Sciences Center (OUHSC) on September 25, 2025, with completion targeted for March 24, 2028. The task order supports further development of mitochondria-targeted honokiol for prevention of lung cancer, specifically addressing both adenocarcinoma and squamous cell carcinoma indications. This delivery order operates under the PREVENT Cancer Preclinical Drug Development Program's...
- This is a $1,201,554.00 firm fixed-price delivery order awarded by the National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on chemoprevention using mitochondria-targeted honokiol in mouse models of lung cancer, specifically adenocarcinoma and squamous cell carcinoma. The contract is part of the National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program, a $149,995,000 multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ)...
- This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The contract is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery, indefinite quantity (IDIQ) vehicle. It is for "OTHER FUNCTIONS - IN VITRO AND IN VIVO AGENT DEVELOPMENT ASSAYS" services with a ceiling value of $1,899.49....
- The National Cancer Institute, a component of the Department of Health and Human Services' National Institutes of Health, awarded an $849,440 firm fixed price contract to the University of Oklahoma Health Sciences Center under the Prevent Preclinical Drug Development Program. The University will deliver on the stated objective of chemoprevention with aerosolized let-7 microRNA in mouse models of non-small cell lung cancer adenocarcinoma and squamous cell carcinoma. Two subcontracts were issued...
- The National Cancer Institute awarded a $982,258 firm fixed price delivery order to the University of Oklahoma Health Sciences Center to support preclinical drug development research focused on preventing lung adenocarcinoma using ONC201, a TRAIL-inducing agent. The task order was issued under the PREVENT Cancer Preclinical Drug Development Program and has an ultimate completion date of September 7, 2026. The work will be performed in Oklahoma City, Oklahoma. This delivery order was awarded...
- The University of Oklahoma Health Sciences Center (OUHSC) was awarded a $909,993.85 firm fixed-price delivery order by the National Cancer Institute on September 21, 2020, for the evaluation of two different classes of compounds—STAT3 inhibitors and selective estrogen receptor modulators (SERMs)—for the prevention of urinary bladder cancer. This delivery order is issued under the PREVENT Cancer Preclinical Drug Development Program, an expansive National Cancer Institute Indefinite...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
- This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...